ARISING HEALTHALIVE. AWAKE. AWARE.Read the magazines →

← All editions

THE ARISING · EDITED READER EDITION

The Arising · November 13 Edited Reader Edition

This edited reader edition includes 2 reviewed articles from November 13, 2026. It is not the complete original issue. It includes 2 of the original 12 stories; 10 are not included here.

Longevity & Healthspan · Long Reads

A Study Found No Clear Drop in Brain Weight With Age Across Four Great Ape Groups

Total brain weight is a broad measure. It cannot show that individual brain regions or cognitive abilities stay unchanged.

How much of the human brain’s aging do we share with our closest living relatives? Research published in the Proceedings of the National Academy of Sciences puts one part of that question to a test: whether the brain as a whole becomes lighter in older animals.

Branka Hrvoj-Mihic and colleagues examined brain weight across the adult age range of chimpanzees, bonobos, gorillas and orangutans. The researchers did not find a statistically clear decline in total brain weight with age in the groups they studied. In a subset of chimpanzees, that result held when the researchers accounted for body weight. The study suggests that marked loss of total brain weight is not a general feature of aging in these apes.

A separate PNAS study in 2011 took a different approach. It compared MRI scans from 99 chimpanzees with scans from 87 humans. Across the age ranges sampled, the human participants had smaller volumes at older ages across the structures measured; the chimpanzee data did not show the same pattern. The ages beyond the maximum lifespan of the chimpanzees contributed importantly to the apparent human decline. That makes a longer lifespan one hypothesis worth testing, not an explanation established by the newer brain-weight study.

There is more to brain aging than weight or volume. A cross-sectional study compares different individuals of different ages, not the same brains tracked over decades. Total brain weight can also look stable while a particular region changes, and neither study shows that the species are free of age-related cognitive change.

For longevity research, the value is in the comparison. Instead of assuming that marked loss of total brain weight must come with aging in all large-brained primates, researchers can ask where the trajectories diverge and why. This work does not establish a preventive treatment or a new clinical test.

Original PNAS study on brain weight in great apes

Earlier PNAS MRI comparison of chimpanzees and humans

Open this article on its own → Explore the related Living Magazine →

Science & Frontiers

The FDA Asks Gene Therapy Makers to Show Potency Across Batches

Final guidance makes the distinction clear: a consistent product is necessary, but it does not prove that a treatment will help patients.

When a cell or gene therapy looks promising in a study, the next patient needs more than a report on the first patients’ results. The developer also has to show that a new batch is capable of the intended biological activity. In November 2026, the FDA issued final guidance on how manufacturers should approach that question.

The guidance replaces the agency’s 2011 document on potency testing for cell and gene therapy products. It recommends a strategy for building confidence in potency throughout a product’s development and manufacture, rather than relying on a single test at the end. The FDA describes the strategy as flexible and grounded in the risks of the particular product. This is guidance for manufacturers, not a new approval or a blanket rule that all therapies must use the same test.

Potency and clinical benefit answer different questions. Potency is about a product’s capacity to perform its intended biological activity. A clinical trial asks whether that activity, in actual patients, produces a meaningful improvement with acceptable harms. Regulators and clinicians need both kinds of evidence. A credible potency result does not show that the treatment works for a particular disease, that its effects will last or that it is safe.

The 8th Cell & Gene Therapy Analytical Development Summit was scheduled for Dec. 1–3 in Boston. Its focus on measurement underscores the industry’s attention to this problem, but a commercial meeting agenda does not establish a finding or endorse a therapy.

For readers following new treatments, the useful questions are separate: did patients benefit in a credible trial, and can the manufacturer show that later batches remain comparable? The FDA guidance is about the second question. It should not be read as an answer to the first.

FDA’s final potency assurance guidance

FDA’s Nov. 2 announcement

Conference organizer’s date and program information

Open this article on its own → Explore the related Living Magazine →

THE ARISING NEWSLETTER

Science moves forward.
Come with it.

Research, clear explanations, and a little room for wonder.
Read and follow The Arising on Substack.

Find The Arising on Substack ↗